A Spanish study shows epigenetic markers in the DNA can predict COVID-19 disease severity. Many of these markers are found in genes linked to immune function and the release of interferon in response to viral infection such as AIM2 and HLA-C.
Clofazimine, which was discovered in 1954, is FDA approved and on the World Health Organization’s List of Essential Medicines. The drug’s utility for COVID-19 was initially identified by screening more than 12,000 drugs from the ReFRAME drug library.
Patients with severe COVID-19 have high levels of immune cells that increase inflammation and promote blood clots and low levels of infection-fighting B and T cells, according to a U.K. study using multi-omics techniques.
The PD-1 checkpoint inhibitor Opdivo (nivolumab) has been approved by the FDA as an initial treatment for advanced gastric cancer, adding to its approvals as a treatment for melanoma and a number of other cancers.
A new sweat sensor can detect seven inflammatory proteins seen at high levels in patients experiencing the kind of extreme immune reaction seen in COVID-19 and in some flu patients, which researchers hope will speed up treatment.
The researchers identified 25 new rare pathogenic variants associated with lung cancer susceptibility and validated five of those variants. Of those five, two variants involved genes with known connections to lung cancer risk, ATM and MPZL2. Three variants involved novel lung cancer susceptibility genes, POMC, STAU2 and MLNR.
The researchers used mRNA technology to code for Cas13a, which destroys parts of the RNA genetic code that viruses use to replicate in cells in the lungs. Using a guide strand, researchers can provide a map that basically tells the Cas13a protein where to attach to the viruses’ RNA and begin to destroy it.
The researchers found that mutations in KMT2C and KMT2D make non-small cell lung cancer more sensitive to Poly (ADP-ribose) polymerase (PARP) inhibitors, which are already approved for treating prostate, pancreatic, ovarian, and breast cancer patients.
Researchers at the Baylor College of Medicine report that they have found that microbes in the gut may contribute to certain symptoms associated with complex neurological disorders, which also suggests that microbe-inspired therapies may one day help to treat them.
Known as Explainable Multi-Omics Graph Integration (EMOGI), the machine learning method predicted 165 new cancer genes by combining multiomics pan-cancer data—such as mutations, copy number changes, DNA methylation and gene expression—together with protein–protein interaction (PPI) networks.
The CDC’s Advisory Committee on Immunization Practices (ACIP) will meet Wednesday to review the six reported cases to assess their potential significance. The FDA plans to conduct its own investigation and will also review the CDC’s analysis.
SARS-CoV-2 affects many parts of the body. Although the primary manifestations of COVID-19 involve the respiratory system, gastrointestinal effects may play a critical role in both disease severity and transmission.
The ABCC1 protein has the ability to break down amyloid plaques in Alzheimer’s disease and researchers show in a new study that increasing expression of this gene may even prevent the neurodegenerative disease from developing in the first place.
A team of researchers from Centre de Recherche en Cancerologie de Marseille (CRCM), INSERM in France have developed a new method for capturing the metabolic signature of pancreatic ductal adenocarcinoma to predict clinical outcomes.
The new automation friendly reagents allow laboratories testing for COVID-19 have a tool that allows them to skip the RNA extraction step of the many testing workflows and move directly to PCR amplification.
A method known as 'Drug Ranking Using Machine Learning' was developed at Queen Mary University in London and is based on machine learning analysis of protein omics data in cancer cells. It was created based on training responses of cancer cells to a panel of cancer drugs and can predict the most appropriate one to use to treat a particular cancer.
The company will expand its health benefits management offerings, as well as make investments in data analytics and innovative health tech
According to the new study, the tumor-penetrating peptide known as iRGD appears to enhance the effects of chemotherapy, reducing metastasis, and increasing survival, to a degree determined by levels of β5 integrin. Essentially, β5 integrin gives chemotherapeutic agents the opportunity to destroy the tumor from within.
The research team drew from Mount Sinai's BioMe BioBank program, a repository of genomic information for diverse populations, for its study. Using machine learning methodology, they identified 17 distinct ethnic communities from among the 30,000 participants in the BioMe BioBank.
The kit is designed for purification of circulating cfNDA and uses silica coated paramagnetic particles to purify cfDNA from less than 1 mL to greater than 10 mL of serum or plasma.
The researchers’ analysis showed low expression of IFNAR2, or high expression of TYK2, are associated with life-threatening disease. Also, transcriptome-wide association in lung tissue revealed that high expression of the monocyte–macrophage chemotactic receptor CCR2 is associated with severe COVID-19.
Under the agreement, Biognosys will leverage its biomarker discovery technologies in conjunction with Siemens’ biomarker assay development, lab testing, and commercialization infrastructure to discover novel biomarkers followed by translation of the biomarkers into validated assays for potential clinical applications.
Almost a dozen antisense treatments have been approved by the FDA to date. Almost all of these are for orphan diseases, including the drug used in this study sepofarsen, which targets Leber congenital amaurosis (LCA), but is specifically designed for LCA patients with the CEP290 mutation.
A new approach developed at Emory University School of Medicine combines genome-wide association study data with human brain proteomic data and has identified 19 genes and 25 brain proteins that could cause depression.
The researchers conclude that isolating residents or staff when they develop symptoms is not sufficient to prevent within-care home spread once the virus has entered the care home. Certain measures may be required on an ongoing basis within care homes when there is sustained community transmission, even when no outbreak is suspected.